Alligator Bioscience announces final terms of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience Announces Positive Outcome of Regulatory Interactions on Phase 3 CMC activities
FDA feedback reinforces manufacturing strategy reducing regulatory risk of the program Feedback confirms completed and planned CMC-work as P ...
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
Today, on 13 January 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follow ...
Alligator Bioscience AB announces outcome of exercise of warrants series TO 9
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
Last day of trading in warrants series TO 9 in Alligator Bioscience AB is 13 December 2024
13 December 2024 is the last day of trading in warrants series TO 9 in Alligator Bioscience AB (“Alligator Bioscience” or the &# ...
Alligator Bioscience publishes financial calendar for 2025
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2025: Extraordinary General ...
Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial
Lund, Sweden, November 27, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Company was notified that th ...
Alligator Bioscience resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program
The board of directors of Alligator Bioscience AB (“Alligator”) has on 3 December 2024 resolved to convert 170,681 series C shar ...
Exercise price determined for the exercise of warrants series TO 9 in Alligator Bioscience AB
Alligator Bioscience AB (“Alligator” or the “Company”) hereby announces that the exercise price for warrants series ...